ABBV vs DE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Deere & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Deere & Company · Industrials
$596.74
-29.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
DE trades at a lower forward P/E
(33.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DE |
| Current Price |
$261.07 |
$596.74 |
| Fair Value Estimate |
$264.30 |
$418.72 |
| Upside to Fair Value |
+1.2%
|
-29.8%
|
| Market Cap |
$461.3B |
$161.1B |
| Forward P/E |
128.0x
|
33.7x
|
| EV / EBITDA |
31.0x
|
19.0x
|
| Price / Sales |
7.3x
|
3.4x
|
| Price / FCF |
22.1x
|
42.8x
|
| Revenue Growth YoY |
+12.4%
|
+6.7%
|
| Gross Margin |
70.7%
|
35.4%
|
| Operating Margin |
27.6%
|
18.4%
|
| Return on Equity |
68.0%
|
18.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.34%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Deere & Company operates in the agricultural machinery sector, providing durable equipment critical to farming and construction industries. The business quality is high, supported by a strong 18.3% return on equity and solid gross and operating margins of 35.4% and 18.4%, respectively. However, the stock is currently overvalued, trading approximately 30% above its fair value estimate of $418.72, …
Accumulation Zones
| Metric |
ABBV |
DE |
| Zone Low |
$198.23 |
$314.04 |
| Zone High |
$224.66 |
$355.91 |
| In Buy Zone? |
No
|
No
|